IP Library › Granted Patent US 12,318,436
Granted Patent B2
US 12,318,436 · App. 17/612,893 · Granted Jun 3, 2025

Composition and method for spray drying an adjuvant vaccine emulsion

Inventors: Ryan Kramer (Lynnwood, WA); Michelle Archer (Seattle, WA); Christopher Fox (Sumner, WA); Reinhard Vehring (Edmonton, CA); Mani Ordoubadi (Edmonton, CA); Mellissa Gomez (Leduc, CA); Nicholas Carrigy (Sherwood Park, CA)
Assignee: ACCESS TO ADVANCED HEALTH INSTITUTE
A61K39/04A61K9/0075A61K31/7016A61K39/39A61K47/44A61P11/00A61K2039/543A61K2039/544A61K2039/55572
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,318,436
App. No.
17/612,893
Granted
Jun 3, 2025
Kind
B2
Abstract

The invention provides for thermostable spray dried formulations including vaccines and pharmaceutical compositions for inducing or enhancing an immune response and methods of use thereof. The spray dried formulations are a dry powder generally comprising an antigen and/or an adjuvant, a metabolizable oil, and one or more excipients.

Claims (36)

1. A spray-dried composition in the form of a dry powder, comprising an effective amount of an attenuated lipid A derivative (ALD), a gel-microparticle comprising squalene, wherein the squalene is present in an oil-in-water emulsion that is liquid at room temperature and trehalose, wherein a particle size of the dry powder has a particle size diameter of less than about 120 μm and the dry powder is formed by spray drying with an outlet relative humidity of less than 10%.

2. The composition of claim 1 , wherein the composition is a vaccine comprising an effective amount of an antigen.

3. The composition of claim 1 , wherein the particle size of the dry powder has a diameter of less than about 20 μm.

4. The composition of claim 1 , wherein the composition is thermostable at a temperature between about 8° C. to about 60° C. for at least 1 month.

5. The composition of claim 4 , wherein the composition is thermostable for at least 3 months.

6. The composition of claim 1 , further comprising 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), Dipalmitoylphosphatidylcholine (DSPC), egg PC, lecithin, polysorbate, or a combination thereof.

7. The composition of claim 1 , wherein the ALD is monophosphoryl lipid A (MPL), 3d-MPL, or glucopyranosyl lipid adjuvant (GLA).

8. The composition of claim 1 , wherein the composition is inhalable.

9. The composition of claim 2 , wherein the antigen is a polypeptide, a nucleic acid encoding a polypeptide, or a pathogen.

10. The composition of claim 8 , wherein the particle size of the dry powder has a diameter of less than about 20 μm.

11. The composition of claim 10 , wherein the particle size has a diameter of less than about 10 μm.

12. The composition of claim 11 , wherein the particle size has a diameter of 100 nm-300 nm.

13. The composition of claim 8 , wherein the composition is thermostable at a temperature between about 8° C. to about 60° C. for at least 1 month.

14. The composition of claim 8 , further comprising a shell formed from a shell former.

15. The composition of claim 14 , wherein the shell former is leucine.

16. The composition of claim 8 , further comprising 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), Dipalmitoylphosphatidylcholine (DSPC), egg PC, lecithin, polysorbate, or a combination thereof.

17. A method for generating a thermostable dry powder vaccine composition, comprising the step of spray drying, in a spray dryer using an atomization gas, an oil-in-water emulsion to obtain a dry powder at process parameters such that the dry powder comprises gel-microparticles, wherein the oil-in-water emulsion comprises (1) an antigen, (2) qualene, (3) trehalose, (4) an attenuated lipid A derivative (ALD), and (5) a shell-former.

18. The method of claim 17 , further comprising, packaging the thermostable dry powder vaccine composition in an aluminum bag with a dessicant pouch and double heat-sealing.

19. The method of claim 17 , the oil-in-water emulsion further comprising 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), Dipalmitoylphosphatidylcholine (DSPC), egg PC, lecithin, polysorbate, or a combination thereof.

20. The method of claim 17 , wherein the process parameters include an atomizing gas pressure of 10 psi, an atomizing gas flow rate of 0.6 mL/min, and a drying gas flow rate of 200 SLPM (standard liters per minute).

21. A method of administering the composition of claim 1 to a subject, comprising administering the spray-dried composition via inhalation or respiratory delivery of the dry powder.

22. The method of claim 21 , wherein the respiratory delivery is via the nasal or pulmonary route.

23. A method of administering the spray-dried composition of claim 1 to a subject, comprising (1) reconstituting the dry powder with an aqueous diluent and (2) administering the reconstituted dry powder via a parenteral route.

24. A method of treating a disease with a respiratory component, comprising administering the spray-dried vaccine composition of claim 2 via inhalation of the dry powder.

25. The method of claim 24 wherein the disease with a respiratory component is Tuberculosis (TB), Influenza (flu), Respiratory syncytial virus infection (RSV), or lung cancer.

26. The composition of claim 1 , wherein the dry powder has an approximately 2-3% moisture content.

27. The composition of claim 1 , wherein the spray-dried composition exhibits colloidal stability as measured by a droplet size of the oil-in-water emulsion following reconstitution of the dry powder being not significantly different than a droplet size of the oil-in-water emulsion before spray drying.

28. The composition of claim 27 , wherein the droplet size of the oil-in-water emulsion both before spray drying and after reconstitution is about 100 nm.

29. The composition of claim 1 , wherein the spray-dried composition exhibits colloidal stability as measured by a polydispersity index (PDI) of the oil-in-water emulsion following reconstitution of the dry powder being not significantly different than a PDI of the oil-in-water emulsion before spray drying.

30. The method of claim 17 , wherein the process parameters include an outlet temperature of about 36° C.

31. The method of claim 17 , wherein the process parameters include an outlet relative humidity of about 7%.

32. The method of claim 17 , wherein the ALD is monophosphoryl lipid A (MPL), 3d-MPL, or glucopyranosyl lipid adjuvant (GLA).

33. The composition of claim 1 , wherein the composition is thermostable at a temperature about 40° C. for at least 3 months.

34. The composition of claim 1 , wherein the outlet relative humidity is about 7%.

35. The composition of claim 1 , wherein the dry powder is formed by spray drying with an outlet temperature of about 36° C.

36. The composition of claim 1 , wherein the outlet relative humidity is about 7% and wherein the dry powder is formed by spray drying with an outlet temperature of about 36° C.

Assignments (2)
CHANGE OF NAME Recorded Oct 24, 2022
From: INFECTIOUS DISEASE RESEARCH INSTITUTE
To: ACCESS TO ADVANCED HEALTH INSTITUTE
Reel/Frame 061764/0158 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2021
From: KRAMER, RYAN; ARCHER, MICHELLE; FOX, CHRISTOPHER; VEHRING, REINHARD; ORDOUBADI, MANI; GOMEZ, MELLISSA; CARRIGY, NICHOLAS
To: INFECTIOUS DISEASE RESEARCH INSTITUTE
Reel/Frame 058168/0666 →
Continuity (2)
Provisional Application 62852983 · May 25, 2019
Related Publication 20220249646A1 · Aug 11, 2022
References Cited (45)
JP 2017502962A · 2015 [cited by applicant]
WO WO2009046440A1 · 2009 [cited by examiner]
WO 2009108689A1 · 2009 [cited by applicant]
WO 2015103167A2 · 2015 [cited by applicant]
WO 2019010560A1 · 2019 [cited by applicant]
WO 2020243115A1 · 2020 [cited by applicant]
Oster et al. 2005 (Comparative study of DNA encapsulation into PLGA microparticles using modified double emulsion methods and spray drying techniques; Journal of Microencapsulation 22(3): 235-244. (Year: 2005). [cited by examiner]
Encina et al. 2016 (Conventional spray-drying and future trends for the microencapsulation of fish oil; Trends in Food Science & Technology; 56: 46-60 (Year: 2016). [cited by examiner]
R. Vehring, “Pharmaceutical Particle Engineering via Spray Drying” Pharmaceutical Research, vol. 25, No. 5, pp. 999-1022, 2007. [cited by applicant]
C. Encina et al., “Conventional spray-drying and future trends for the microencapsulation of fish oil,” Trends in Food Science & Technology, vol. 56, pp. 46-60, 2016. [cited by applicant]
S. Bertholet et al., “A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant [cited by applicant]
W. H. Organization, “Global Tuberculosis Report,” World Health Organization, Geneva, 2018. [cited by applicant]
R. N. Coleret al., “The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial,” Nature Partner Journals, vol. 3, No. 34, 2018. [cited by applicant]
C. B. Fox et al., “Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions,” Colloids and Surfaces B; Biointerfaces, vol. 65, pp. 98-105, 2008. [cited by applicant]
A. G. Floyd, “Top ten considerations in the development of parenterial emulsions,” Pharmaceutical Science and Technology Today, vol. 2, No. 4, pp. 134-143, 1999. [cited by applicant]
R. M. Kramer et al., “Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach,” International Journal of Nanomedicine, vol. 13, pp. 3689-3711, 2018. [cited by applicant]
M. T. Orr et al., “Elimination of the cold-chain dependance of a nanoemulsion adjuvant vaccine against tuberculois by lyophilization,” Journal of Controlled Release, vol. 10, No. 177, pp. 20-26, 2014. [cited by applicant]
H. Schwartzbach, “Achieving aseptic drying with spray drying technologies,” Pharmaceutical Technology Europe, vol. 23, No. 9, 2011. [cited by applicant]
International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use, “ICH Harmonised Tripartite Guideline—Stability Testing of New Drug Substances and Products Q1A (R2),… [cited by applicant]
S. Ohtake et al., “Trehalose: current use and future applications,” Journal of Pharmaceutical Sciences, vol. 100, No. 6, pp. 2020-2053, 2011. [cited by applicant]
D. Zhou et al., “Physical stability of amorphous pharmaceuticals: Importance of configurational thermodynamic quantities and molecular mobility,” Journal of Pharmaceutical Sciences, vol. 91, No. 8, pp. 1863-1872, Aug. 2… [cited by applicant]
M. Gordon et al., “Ideal copolymers and the second-order transitions of synthetic rubbers. i. non-crystalline copolymers,” Journal of Applied Chemistry, vol. 2, No. 9, pp. 493-500, Sep. 1952. [cited by applicant]
T. Chen et al., “Literature review: supplemented phase diagram of the trehalose-water binary mixture,” Cryobiology, vol. 40, No. 3, pp. 277-282, 2000. [cited by applicant]
H. A. Iglesias et al., “Adsorption isotherm of amorphous trehalose,” Journal of the Science of Food and Agriculture, vol. 75, No. 2, pp. 183-186, Mar. 26, 1999. [cited by applicant]
K. D. Roe et al., “Glass transition and crystallization of amorphous trehalose-sucrose mixtures,” International Journal of Food Properties, vol. 8, No. 3, pp. 559-574, 2005. [cited by applicant]
R. Vehring et al., “Particle formation in spray drying,” Aerosol Science, vol. 38, pp. 728-746, 2007. [cited by applicant]
J. Ivey et al., “Dried corticosteroid particle formation from evaporating monodisperse propellant solution droplets,” in AAPS Annual Meeting and Exposition, Denver, 1 page, 2016. [cited by applicant]
S. Hoe et al., “Use of a fundamental approach to spray-drying formulation design to facilitate the development of multi-component dry powder aerosols for respiratory drug delivery,” Pharmaceutical Research, vol. 32, No.… [cited by applicant]
M. Y. Chan et al., “Particle sizing of nanoparticle adjuvant formulations by dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA),” Methods in Molecular Biology, vol. 1494, pp. 239-252, 2017. [cited by applicant]
H. Wang et al., “Macro-Raman spectroscopy for bulk composition and homogeneity analysis of multi-component pharmaceutical powders,” Journal of Pharmaceutical and Biomedical Analysis, vol. 141, pp. 180-191, 2017. [cited by applicant]
C. Krogsgard Nielsen et al., “Enhancing the antibacterial efficacy of isoeugenol by emulsion encapsulation,” International Journal of Food Microbiology, vol. 229, pp. 7-14, 2016. [cited by applicant]
N. Mlalila et al., “Effects of spray-drying on w/o/w multiple emulsions prepared from a stearic acid matrix,” Nanotechnology, Science and Applications, vol. 7, pp. 105-112, 2014. [cited by applicant]
C. Lee et al., “Raman spectra of planar supported lipid bilayers,” Biochimica et Biophysica Acta, vol. 1711, No. 1, pp. 59-71, Jun. 2005. [cited by applicant]
M. Bringas-Lantigua et al., “Influence of spray-dryer air temperatures on encapsulated mandarin oil,” Drying Technology, vol. 29, No. 5, pp. 520-526, 2011. [cited by applicant]
Office Action for related patent application from China CIPO, application No. 202080048526, mailed Sep. 28, 2023, 17 pages (with translation). [cited by applicant]
Office Action for related matter Chinese Application No. 2020800485256 dated May 1, 2024, 13 pages. [cited by applicant]
PCT/US2020/034595—International Search Report and Written Opinion, mailed Sep. 22, 2020, 14 pages. [cited by applicant]
L. Garcia-Contreras, et al., “Immunization by a Bacterial Aerosol”, Proceedings of the National Academy of Sciences, vol. 105, No. 12, Mar. 25, 2008, pp. 4656-4660. [cited by applicant]
Office Action for related matter Japan Patent Application No. 2021-569917, dated Aug. 1, 2024, 7 pages (with translation). [cited by applicant]
Kanojia, et al., “Developments in the formulation and delivery of spray dried vaccines”, Human Vaccines & Immunotherapeutics, 13:10, 2364-2378, Oct. 18, 2017, 17 pages. [cited by applicant]
Munoz,-Ibanez, et al., “Changes in oil-in-water emulsion size distribution during the atomization step in speay-drying encapsulation,” Journal of Food Engineering, 167, Feb. 7, 2015, 122-132. [cited by applicant]
Related matter CN Patent Application No. 2020800485256 mailed Oct. 23, 2024, 8 pages. [cited by applicant]
Related family patent Decision of Refusal for Japanese Patent Application No. 2021-569917, dated Feb. 26, 2025, 8 pages (including translation). [cited by applicant]
Kanojia, G. et al., “Developments in the formulation and delivery of spray dried vaccines”, Human Vaccines & Immunotherapies, 2017, vol. 13, No. 10, pp. 2364-2378. [cited by applicant]
Munoz-Ibanez, M. et al., “Changes in oil-in-water emulsion size distribution during the atomization step in spray-drying encapsulation”, Journal of Food Engineering, 2015, vol. 167, pp. 122-132. [cited by applicant]